Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 10: 421, 2019.
Article in English | MEDLINE | ID: mdl-30941122

ABSTRACT

Mycobacterium tuberculosis (Mtb) can subvert the host defense by skewing macrophage activation toward a less microbicidal alternative activated state to avoid classical effector killing functions. Investigating the molecular basis of this evasion mechanism could uncover potential candidates for host directed therapy against tuberculosis (TB). A limited number of miRNAs have recently been shown to regulate host-mycobacterial interactions. Here, we performed time course kinetics experiments on bone marrow-derived macrophages (BMDMs) and human monocyte-derived macrophages (MDMs) alternatively activated with IL-4, IL-13, or a combination of IL-4/IL-13, followed by infection with Mtb clinical Beijing strain HN878. MiR-143 and miR-365 were highly induced in Mtb-infected M(IL-4/IL-13) BMDMs and MDMs. Knockdown of miR-143 and miR-365 using antagomiRs decreased the intracellular growth of Mtb HN878, reduced the production of IL-6 and CCL5 and promoted the apoptotic death of Mtb HN878-infected M(IL-4/IL-13) BMDMs. Computational target prediction identified c-Maf, Bach-1 and Elmo-1 as potential targets for both miR-143 and miR-365. Functional validation using luciferase assay, RNA-pulldown assay and Western blotting revealed that c-Maf and Bach-1 are directly targeted by miR-143 while c-Maf, Bach-1, and Elmo-1 are direct targets of miR-365. Knockdown of c-Maf using GapmeRs promoted intracellular Mtb growth when compared to control treated M(IL-4/IL-13) macrophages. Meanwhile, the blocking of Bach-1 had no effect and blocking Elmo-1 resulted in decreased Mtb growth. Combination treatment of M(IL-4/IL-13) macrophages with miR-143 mimics or miR-365 mimics and c-Maf, Bach-1, or Elmo-1 gene-specific GapmeRs restored Mtb growth in miR-143 mimic-treated groups and enhanced Mtb growth in miR-365 mimics-treated groups, thus suggesting the Mtb growth-promoting activities of miR-143 and miR-365 are mediated at least partially through interaction with c-Maf, Bach-1, and Elmo-1. We further show that knockdown of miR-143 and miR-365 in M(IL-4/IL-13) BMDMs decreased the expression of HO-1 and IL-10 which are known targets of Bach-1 and c-Maf, respectively, with Mtb growth-promoting activities in macrophages. Altogether, our work reports a host detrimental role of miR-143 and miR-365 during Mtb infection and highlights for the first time the role and miRNA-mediated regulation of c-Maf, Bach-1, and Elmo-1 in Mtb-infected M(IL-4/IL-13) macrophages.


Subject(s)
Adaptor Proteins, Signal Transducing/immunology , Basic-Leucine Zipper Transcription Factors/immunology , Macrophages/microbiology , MicroRNAs/immunology , Mycobacterium tuberculosis/growth & development , Proto-Oncogene Proteins c-maf/immunology , Animals , Interleukin-13/pharmacology , Interleukin-4/pharmacology , Macrophages/drug effects , Macrophages/immunology , Male , Mice, Inbred BALB C , Tuberculosis/genetics , Tuberculosis/immunology , Tuberculosis/microbiology
2.
Nat Rev Immunol ; 18(6): 374-389, 2018 06.
Article in English | MEDLINE | ID: mdl-29581532

ABSTRACT

The C-type lectins are a superfamily of proteins that recognize a broad repertoire of ligands and that regulate a diverse range of physiological functions. Most research attention has focused on the ability of C-type lectins to function in innate and adaptive antimicrobial immune responses, but these proteins are increasingly being recognized to have a major role in autoimmune diseases and to contribute to many other aspects of multicellular existence. Defects in these molecules lead to developmental and physiological abnormalities, as well as altered susceptibility to infectious and non-infectious diseases. In this Review, we present an overview of the roles of C-type lectins in immunity and homeostasis, with an emphasis on the most exciting recent discoveries.


Subject(s)
Lectins, C-Type/immunology , Adaptive Immunity , Animals , Arthritis/immunology , Atherosclerosis/immunology , Autoimmunity , Cell Death/immunology , Diabetes Mellitus, Type 1/immunology , Homeostasis/immunology , Host Microbial Interactions/immunology , Host-Parasite Interactions/immunology , Humans , Hypersensitivity/immunology , Immunity, Innate , Inflammation/immunology , Lectins, C-Type/antagonists & inhibitors , Lectins, C-Type/chemistry , Models, Immunological , Neoplasms/immunology , Signal Transduction/immunology
3.
Ann Rheum Dis ; 75(7): 1386-91, 2016 07.
Article in English | MEDLINE | ID: mdl-26275430

ABSTRACT

BACKGROUND: Myeloid inhibitory C-type lectin-like receptor (MICL, Clec12A) is a C-type lectin receptor (CLR) expressed predominantly by myeloid cells. Previous studies have suggested that MICL is involved in controlling inflammation. OBJECTIVE: To determine the role of this CLR in inflammatory pathology using Clec12A(-/-) mice. METHODS: Clec12A(-/-) mice were generated commercially and primarily characterised using the collagen antibody-induced arthritis (CAIA) model. Mechanisms and progress of disease were characterised by clinical scoring, histology, flow cytometry, irradiation bone-marrow chimera generation, administration of blocking antibodies and in vivo imaging. Characterisation of MICL in patients with rheumatoid arthritis (RA) was determined by immunohistochemistry and single nucleotide polymorphism analysis. Anti-MICL antibodies were detected in patient serum by ELISA and dot-blot analysis. RESULTS: MICL-deficient animals did not present with pan-immune dysfunction, but exhibited markedly exacerbated inflammation during CAIA, owing to the inappropriate activation of myeloid cells. Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA. In wild-type mice the administration of such antibodies recapitulated the Clec12A(-/-) phenotype. CONCLUSIONS: MICL plays an essential role in regulating inflammation during arthritis and is an autoantigen in a subset of patients with RA. These data suggest an entirely new mechanism underlying RA pathogenesis, whereby the threshold of myeloid cell activation can be modulated by autoantibodies that bind to cell membrane-expressed inhibitory receptors.


Subject(s)
Arthritis, Experimental/genetics , Arthritis, Rheumatoid/genetics , Lectins, C-Type/physiology , Receptors, Mitogen/physiology , Animals , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/etiology , Arthritis, Rheumatoid/pathology , Autoantibodies/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Lectins, C-Type/deficiency , Lectins, C-Type/immunology , Mice , Myeloid Cells/metabolism , Polymorphism, Genetic , Receptors, Mitogen/deficiency , Receptors, Mitogen/immunology , Synovial Membrane/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...